Study wrapper · #228
Novel orally active growth hormone secretagogues.
Editor's note
A medicinal-chemistry study in which ipamorelin serves as the lead compound for designing smaller, orally bioavailable GH secretagogues. By shrinking the molecule and reducing hydrogen-bonding groups, the researchers produced compounds (molecular weight 500-650) that retained GH-releasing potency in swine while achieving oral bioavailability in dogs in the 10-55% range, with the most potent showing an ED50 of 30 nmol/kg. This is drug-discovery and structure-activity work, not a study of ipamorelin's effects; its interest for readers is contextual, showing how ipamorelin anchored efforts to make an oral version of an injectable peptide class. The endpoints are receptor-level potency and bioavailability in animals; there are no clinical outcomes here. For Ipamorelin, this is preclinical chemistry. Human data would be required before any therapeutic conclusion about these compounds.
Plain-language abstract
This study aimed to design growth-hormone-releasing drugs that could be taken by mouth, using the peptide ipamorelin as the starting point. Peptides like ipamorelin usually must be injected because they are poorly absorbed from the gut. The researchers made ipamorelin smaller and chemically simpler to improve oral absorption, while trying to keep its ability to trigger growth-hormone release. They screened all the new compounds in a rat pituitary-cell test, then tested the promising ones for potency in pigs and for oral absorption in dogs. Most of the new compounds had oral absorption in the range of 10-55%, and the most potent one triggered a half-maximal growth-hormone response at a dose of 30 nmol per kilogram of body weight. The researchers concluded they had found a new class of small, orally active growth-hormone-releasing compounds. This is laboratory and animal research; it does not test these compounds in people.